Universitéde Montreal

Rsem, Limited Partnership

Jean-Sébastien Delisle

Guy Sauvageau

Pierre Thibault

Claude Perreault

Sébastien Lemieux

Jalila Chagraoui

Diana Paola Granados

Jean Roy

Silvy Lachance

Sandra Cohen

It is provided a method of expanding dendritic (DC) cells and/or natural killer (NK) cells in vivo in a patient comprising the steps of producing a graft of stem and progenitor cells cultured with UM171 or analogues therefrom and expanded before being administered to the patient. The expansion or increase in dendritic (DC) cells and/or natural killer (NK) cells population in the patient results in an increase immune response reducing transplant related mortality (TRM), severe graft-versus-host disease (GVHD), relapse, and/or severe viral infections.

Expansion of NK and DC cells in vivo mediating immune response

Novel minor histocompatibility antigens (MiHAs) are described. These novel MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel MiHAs are also described. The present application also discloses the use of these novel MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.

Minor histocompatibility antigens and uses thereof

Growing community of inventors

Québec, Canada

Jean-Sébastien Delisle